A recent in vivo study reported that natural Aβ-antibodies (Nabs-Aβ) isolated from hIVIG reduced amyloid plaque burden in 3-month-old mice but not in 12-month-old APP transgenic mice [24]. This evidence concerns the gene APP and amyloidosis.